New Strong Sell Stocks for July 29th
ARDX, BDORY and AXSM have been added to the Zacks Rank #5 (Strong Sell) List on July 29, 2026.
Zacks Investment Research7/29/2026Negative
ARDX
Ardelyx IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$1.26B
P/E Ratio
—
EPS
$-0.24
Beta
0.60
52W High
$8.40
52W Low
$4.08
50-Day MA
$5.61
200-Day MA
$6.03
Dividend Yield
—
Profit Margin
-13.60%
Forward P/E
40.65
PEG Ratio
-0.08
About Ardelyx Inc
Ardelyx, Inc., a biopharmaceutical company, develops and sells drugs for the treatment of kidney and cardiorenal diseases in the United States and internationally. The company is headquartered in Fremont, California.
Fundamentals
| Revenue (TTM) | $427.68M |
| Gross Profit (TTM) | $318.86M |
| EBITDA | $-34.05M |
| Operating Margin | -34.70% |
| Return on Equity | -39.50% |
| Return on Assets | -5.11% |
| Revenue/Share (TTM) | $1.76 |
| Book Value | $0.60 |
| Price-to-Book | 8.41 |
| Price-to-Sales (TTM) | 2.94 |
| EV/Revenue | 2.853 |
| EV/EBITDA | 130.88 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 27.50% |
| Shares Outstanding | $247.03M |
| Float | $219.80M |
| % Insiders | 3.26% |
| % Institutions | 70.79% |
Historical Volatility
HV 10-Day
29.16%
HV 20-Day
27.56%
HV 30-Day
44.47%
HV 60-Day
46.03%
HV Rank
24.2%
Volatility is currently contracting
Analyst Ratings
Consensus ($16.30 target)
1
Strong Buy10
BuyLatest News
Ardelyx to Report Second Quarter 2026 Financial Results on August 6, 2026
WALTHAM, Mass., July 23, 2026 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX) (“Ardelyx” or the “Company”), a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative medicines that meet significant unmet medical needs, today announced that management will host a webcast and conference call on Thursday, August 6, 2026, at 4:30 p.m.
GlobeNewsWire7/23/2026Neutral
New Strong Sell Stocks for July 23rd
ABR, ARDX and RGNX have been added to the Zacks Rank #5 (Strong Sell) List on July 23, 2026.
Zacks Investment Research7/23/2026Negative
Ardelyx Eyes $500M+ Revenue as IBSRELA Growth Puts Profitability Within Reach
Ardelyx NASDAQ: ARDX executives said at the Jefferies Global Healthcare Conference that the company is focused on expanding demand for its commercial products, IBSRELA and XPHOZAH, while continuing to invest in its pipeline and positioning the business for sustainable profitability.
MarketBeat6/4/2026Positive
Ardelyx to Participate at the Jefferies Global Healthcare Conference 2026
WALTHAM, Mass., May 19, 2026 (GLOBE NEWSWIRE) -- Ardelyx Inc. (Nasdaq: ARDX), (“Ardelyx” or the “Company”) a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative medicines that meet significant unmet medical needs, today announced its participation in a fireside chat at the Jefferies Global Healthcare Conference 2026 on June 3 at 9:55 a.m. ET in New York.
GlobeNewsWire5/19/2026Neutral
Ardelyx: Low Price, But High Implied Valuation
Ardelyx (ARDX) is rated Buy, driven by robust commercial execution of IBSRELA and XPHOZAH, and management's $1B revenue target by FY2029. ARDX's ACCEL Phase III trial offers significant upside optionality, potentially tripling IBSRELA's addressable market if successful. DCF analysis yields a base-case share price of $24.27, well above current levels, even excluding ACCEL trial upside.
Seeking Alpha5/8/2026Positive
Ardelyx, Inc. (ARDX) Q1 2026 Earnings Call Transcript
Ardelyx, Inc. (ARDX) Q1 2026 Earnings Call Transcript
Seeking Alpha5/1/2026Neutral
Ardelyx Reports First Quarter 2026 Financial Results and Provides Business Update
Q1 2026 total product revenue of $93.4 million, reflecting 38% growth year-over-year IBSRELA Q1 2026 revenue growth of 58% year-over-year to $70.1 million; Reiterating guidance of $410-$430 million Strong financial position with $238.1 million in cash, cash equivalents and investments as of March 31, 2026 Conference call scheduled for 4:30 PM Eastern Time WALTHAM, Mass., April 30, 2026 (GLOBE NEWSWIRE) -- Ardelyx Inc. (Nasdaq: ARDX), (“Ardelyx” or the “Company”) a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative medicines that meet significant unmet medical needs, today reported financial results for the first quarter ended March 31, 2026, and provided a business update.
GlobeNewsWire4/30/2026Neutral
Neurocrine Biosciences (NBIX) Reports Next Week: Wall Street Expects Earnings Growth
Neurocrine (NBIX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks Investment Research4/28/2026Positive
Ardelyx Announces Abstract Accepted for Poster Presentation at the NKF's Spring Clinical Meetings
Presentation evaluates the long-term impact of XPHOZAH® on serum electrolytes and select nutrition biomarkers Presentation evaluates the long-term impact of XPHOZAH® on serum electrolytes and select nutrition biomarkers
GlobeNewsWire4/27/2026Neutral
Turn research into an automated options-selling system
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on ARDX and any ticker you trade — then tracks every position and per-strategy win rate.
More HEALTHCARE Stocks
Data last updated: 7/29/2026